Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Researchers at the UConn Center on Aging have uncovered causal links between depression and Alzheimer’s disease and related ...

Among 24 such systems (called devices in FDA parlance) authorized since 2015, FDA summaries for 14 lacked data on the ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Let’s keep it simple: If you want to delay Alzheimer’s onset, focus on walking and adding nutritious foods, such as walnuts, ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

New tests and new treatments are presenting more options for certain patients with Alzheimer's disease. “Today a confluence ...

A new study reveals that fragmented sleep causes cellular damage to the brain's blood vessels, providing further evidence to ...

The Alzheimer’s Association has issued its first clinical practice guideline on the use of blood tests to help diagnose ...

The prospective cohort study, published in The Journal of Nutrition, found that consuming one or more eggs per week was ...